Lanicemine

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression.^[1][2] Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.^[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.^[4]

Lanicemine

Clinical data
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name (1S)-1-Phenyl-2-pyridin-2-ylethanamine
CAS Number	153322-05-5
PubChem CID	9794203
IUPHAR/BPS	7681
ChemSpider	7969970
UNII	9TMU325RK3
CompTox Dashboard (EPA)	DTXSID30870011
Chemical and physical data
Formula	C13H14N2
Molar mass	198.269 g·mol−1
3D model (JSmol)	Interactive image
SMILES N[C@H](C1=CC=CC=C1)CC2=NC=CC=C2
InChI InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1 Key:FWUQWDCOOWEXRY-ZDUSSCGKSA-N

See also

• 4-Chlorokynurenine
• AD-1211
• Apimostinel
• CERC-301
• Diphenidine
• Ephenidine
• Esketamine
• Lefetamine
• Memantine
• Methoxphenidine
• MT-45
• Rapastinel